Chinese biopharma firm MabPlex nets $71m in Series B round

MabPlex International, a Chinese contract developer and manufacturer of biopharmaceuticals

MabPlex International, a Chinese contract developer and manufacturer of biopharmaceuticals, has garnered over 500 million yuan ($71 million) in a Series B round of financing led by private equity firms DT Capital Partners and Huajin Capital.

Global healthcare investment specialist OrbiMed, Chinese insurer Sunshine Insurance Group, the alternative investments unit of China Merchants Securities, Chinese venture capital firm Finnova Capital, private equity fund Horus Capital, and Beijing-based asset manager Qiandao Fund participated in the deal, said DT Capital Partners in a WeChat post on Monday.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter